The largest database of trusted experimental protocols
> Anatomy > Body Part > Graafian Follicle

Graafian Follicle

The Graafian follicle is a mature ovarian follicle that contains a secondary oocyte and is ready for ovulation.
It is named after the Dutch anatomist Regnier de Graaf, who first described it in the 17th century.
The Graafian follicle is a key structure in the female reproductive system, playing a crucial role in the menstrual cycle and ovulation.
Researchers studying the Graafian follicle can utilize PubCompare.ai's AI-driven platform to optimize their research protocols, explore a vast library of relevant literature, preprints, and patents, and find the best protocols and products using intelligent comparisons - taking the guesswork out of their research with PubCompare.ai's powerful tools.

Most cited protocols related to «Graafian Follicle»

Fixed ovaries were processed for microscopy and subsequently the entire ovary was sectioned at 8 µm. Every 5th ovarian section was stained with haematoxylin and eosin for morphometric analysis. In order to prevent multiple counts of the same follicle, only those follicles with a visible oocyte nucleus were included. Since oocyte nuclei measured between 20–30 µm in diameter, counting every 5th section of the ovary ensured a distance of 40 µm between analysed sections, preventing multiple counts of the same ovarian follicle. Follicle classification based on characteristics proposed by Hirshfield & Midgley [66] (link) was as follows: type 1: primordial follicle, one layer of flattened granulosa cells surrounding the oocyte; type 2: primary follicle, one to fewer than two complete layers of cuboidal granulosa cells; type 3: secondary follicle, an oocyte surrounded by greater than one layer of cuboidal granulosa cells, with no visible antrum; type 4: antral follicle, an oocyte surrounded by multiple layers of cuboidal granulosa cells and containing one or more antral spaces, cumulus oophorus and theca layer may also have been evident. Total volume of each section was calculated (area of the section x thickness of the section) and follicle counts for each animal were corrected for the total volume of ovarian tissue counted. All follicle counts were then expressed as number of follicles counted per mm3 of ovarian tissue counted.
Full text: Click here
Publication 2010
Animals Antral Cell Nucleus Cuboid Bone Eosin Graafian Follicle Granulosa Cell Hair Follicle Microscopy Oocytes Ovarian Follicle Ovary Tissues
Duplicate 10 g samples of each tissue were grounded in liquid nitrogen with mortar and pestle. From the ovary of POST heifers, this included tissue composing antral follicles and the corpus luteum, whereas from PRE heifers, this only included tissue containing antral follicles. Total RNA was purified using a Trizol protocol (Invitrogen, Carlsbad, CA). Quality was evaluated using the RNA Integrity Number (RIN) value from the Experion automated electrophoresis system (BioRad, Hercules, CA). The RIN values ranged from 7.6 to 9.8 in the tissues samples; lower RIN values were observed in adipose samples. As described by Cánovas et al. [83] (link), mRNA was purified, fragmented, and converted to cDNA. Adapters were ligated to the ends of double-stranded cDNA and PCR amplified to create libraries. These procedures were executed with the TruSeq RNA Sample Preparation kit (Illumina, San Diego, CA).
Sequencing was completed with an Illumina HiSeq analyzer that yielded 100 bp single read sequences with exception of two hypothalamus samples done earlier on an Illumina GA II sequencer that yielded 36 bp sequence reads. Sequence reads were assembled to the annotated UMD3.1 bovine reference genome (release 74; ftp://ftp.ensembl.org/pub/release-74/genbank/bos_taurus/). Quality control and RNA-Seq expression analysis was performed using procedures described by Cánovas et al. [84] (link) and using the CLC Genomics workbench software (CLC Bio, Aarhus, Denmark). Transcript levels were quantified in reads per kilobase of exon per million reads (RPKM). By normalizing for RNA length and total reads in each sample, the RPKM measure facilitated comparisons of transcript levels both within and between tissues [24] (link). In the present study, we used a threshold of RPKM ≥0.2 to select genes expressed in a given sample [22] (link), [23] (link).
Full text: Click here
Publication 2014
BP 100 Cattle Corpus Luteum DNA, Complementary Electrophoresis Exons Genes Genome Graafian Follicle Hypothalamus Multiple Acyl Coenzyme A Dehydrogenase Deficiency Nitrogen Obesity Ovary RNA, Messenger Tissues Transcription, Genetic trizol
Oocytes were processed as previously described [5] (link). Pig ovaries were purchased from a local slaughter house. Briefly, cumulus oocyte complexes (COCs) were aspirated from antral follicles and washed with maturation medium (Tissue Culture Medium 199) (Gibco) supplemented with 0.1% (w/v) polyvinyl alcohol (Sigma), 3.05 mM d-glucose, 0.91 mM sodium pyruvate (Sigma), 0.57 nM cysteine (Sigma), 0.5 µg/ml LH (Sigma), 0.5 µg /ml FSH (Sigma), 10 ng/ml epidermal growth factor (Sigma), 10% (v/v) porcine follicular fluid, 75 µg /ml penicillin G, and 50 µg /ml streptomycin. The COCs were then transferred to a four-well multidish (Nunc) containing 500 µl of the maturation medium covered with mineral oil and pre-equilibrated at 39°C overnight. After 42–44 h of incubation, the oocytes were released from the COCs by vigorous vortex for 4 min in TL-Hepes containing 0.1% polyvinyl alcohol and 0.1% hyaluronidase (Sigma). The polar body and associated metaphase plate of the oocytes were aspirated using glass pipettes in micromanipulation medium supplemented with 7.5 µg/ml cytochalasin B. Denuded oocytes were used as the recipients for SCNT.
The transgenic PFFs were thawed and grown to subconfluency prior to SCNT. Cells with uniform co-expression of the four fluorescent proteins were selected under fluorescent microscopy and used as donor cells that were injected into the perivitelline space of the oocytes. The oocyte-donor cell complexes were activated to fuse and become reconstructed embryos with two successive DC pulses at 1.2 kv/cm for 30 µs using an electrofusion instrument (BLS). The reconstructed embryos were cultured in embryo-development medium PZM3 at 39°C overnight and then surgically transferred to recipient gilts exhibiting natural estrus. The pregnancy status of the gilts was monitored weekly using an ultrasound scanner beginning on Day 24 after the implantation. All cloned piglets were delivered by natural birth. To monitor in vitro development, transgenic and nontransgenic SCNT embryos were cultured for 6 days until they reached the blastocyst stage.
Full text: Click here
Publication 2011
Animals, Transgenic Blastocyst Cells Culture Media Cysteine Cytochalasin B Embryo Embryonic Development Epidermal growth factor Estrus Follicular Fluid Glucose Graafian Follicle HEPES Hyaluronidase Metaphase Micromanipulation Microscopy Natural Childbirth Oil, Mineral Oocytes Operative Surgical Procedures Ovary Ovum Implantation Penicillin G Pigs Polar Bodies Polyvinyl Alcohol Pregnancy Proteins Pulse Rate Pyruvate Sodium Streptomycin Tissue Donors Tissues Ultrasonics
A total of 750 infertile women 18 to 40 years of age with the polycystic ovary syndrome who had no major medical disorders and who were not taking confounding medications (primarily sex steroids, other infertility drugs, and insulin sensitizers, as described in the study protocol), their male partners, and their neonates participated in the study.9 (link) We used modified Rotterdam criteria1 to diagnose the polycystic ovary syndrome. Accordingly, all participating women had ovulatory dysfunction combined with hyperandrogenism (on the basis of hirsutism9 (link) or an elevated testosterone level10 (link)), polycystic ovaries (defined by an increased number of small antral follicles [≥12 follicles that were <10 mm in diameter] or an increased individual ovarian volume [>10 cm3] in ≥1 ovary), or both.9 (link) Other disorders that mimic the polycystic ovary syndrome, including thyroid disease and prolactin excess, were ruled out.
Additional eligibility criteria were at least one patent fallopian tube and a normal uterine cavity, as determined by sonohysterography (on the basis of the presence of free fluid in the pelvis), hysterosalpingography, a combined hysteroscopy and laparoscopy, or evidence of an intrauterine pregnancy within the previous 3 years; a male partner with a sperm concentration of at least 14 million per milliliter, with documented motility according to World Health Organization cutoff points,11 (link) in at least one ejaculate during the previous year; and a commitment on the part of the women and their partners to have regular intercourse during the study with the intent of pregnancy.
Publication 2014
Coitus Dental Caries Diagnosis Eligibility Determination Fallopian Tubes Female Infertility Fertility Agents Gonadal Steroid Hormones Graafian Follicle Hair Follicle Hyperandrogenism Hysterosalpingography Hysteroscopy Infant, Newborn Insulin Laparoscopy Males Motility, Cell Ovary Ovulation Pelvis Pharmaceutical Preparations Polycystic Ovary Syndrome Pregnancy Prolactin Sperm Testosterone Thyroid Diseases Uterus Woman
Women aged 18–36 years with a body weight of more than 60 kg up to and including 90 kg, a BMI of 18–32 kg/m2, a menstrual cycle length of 24–35 days, access to ejaculatory sperm and an indication for controlled ovarian stimulation (COS) before IVF or ICSI were eligible to enroll in the study. Patients who had a (history of) an endocrine abnormality, an abnormal outcome of blood biochemistry or hematology, an abnormal cervical smear, a chronic disease, relevant ovarian-, tubal- or uterine-pathology that could interfere with the COS treatment (e.g. endometrioma >0 mm or fibroids ≥5 cm), embryo implantation or pregnancy were not to be included in the trial. Patients who had a history of ovarian hyperresponse (more than 30 follicles ≥11 mm) or ovarian hyperstimulation syndrome (OHSS), polycystic ovary syndrome (PCOS) or a basal antral follicle count (AFC) of more than 20 on ultrasound (<11 mm, both ovaries combined) were excluded from participation. Other exclusion criteria included a previously low ovarian response to FSH or hMG treatment (i.e. cycle cancelled due to insufficient ovarian response or less than four oocytes obtained), an FSH or LH over 12 IU/L in the early follicular phase, more than three consecutive unsuccessful IVF cycles since the last ongoing pregnancy, a history of recurrent miscarriage (three or more), or currently smoking more than five cigarettes per day.
Publication 2009
Abortion, Habitual BLOOD Body Weight Disease, Chronic Ejaculation Endometrioma Fibroid Tumor Graafian Follicle Hair Follicle Menstrual Cycle Menstrual Cycle, Proliferative Phase Oocytes Ovarian Hyperstimulation Syndrome Ovarian Stimulation Ovary Ovum Implantation Patients Polycystic Ovary Syndrome Pregnancy Sperm Sperm Injections, Intracytoplasmic System, Endocrine Ultrasonography Uterus Vaginal Smears Woman

Most recents protocols related to «Graafian Follicle»

This retrospective cohort study was performed between January 2017 and January 2022 at the Fertility Unit of the Hospital Jiaxing Maternity and Child Health Care Hospital, Zhejiang, China. All the studies were conducted in accordance with the Declaration of Helsinki (1964). Inclusion criteria for eligible patients were as follows: body mass index (BMI ≥ 30 kg/m2); age 18 to 38 years; first IVF/intracytoplasmic sperm injection (ICSI) cycle; short-acting gonadotropin-releasing hormone (GnRH) agonist long protocol; women were excluded from the trial if they had diminished ovarian reserve (defined as an antral follicle count of ≤5 or baseline follicle-stimulating hormone levels ≥ 10 IU/L), irregular uterine bleeding, oocyte donation, pre-implantation genetic diagnosis, and Cushing syndrome.
We advised obese women to participate in a weight management program for 3 to 6 months before undergoing their first IVF/ICSI cycle. Women were divided into 2 groups according to the weight loss goal of 5%: weight reduction group A (≥weight loss goal of 5%) and control group A (
Publication 2023
Children's Health Cushing Syndrome Diagnosis Fertility Gonadorelin Graafian Follicle Human Follicle Stimulating Hormone Index, Body Mass Obesity Oocyte Donation Ovarian Reserve Ovum Implantation Patients Sperm Injections, Intracytoplasmic Woman
All women underwent controlled ovarian stimulation (COS) with a GnRH antagonist fixed regimen. Bilateral antral follicles (10mm) were counted by transvaginal ultrasonography on the second day of the menstrual cycle, and women started COS treatment with gonadotrophins (Gonal-F, Merck Serono Europe Ltd or Puregon, N. V. Organon). The levels of serum progesterone (SP) were measured using an automated electrochemiluminescence immunoassay (Roche Diagnostics Elecsys Cortisol II assays and COBAS E801), and values were expressed in ng/ml. At our center, the starting dose of gonadotrophins was 150 IU/day for women aged ≤ 34 years, with BMI <24 kg/m2, 6≤AFC<15, and the dosage would be increased if the woman was older (age ≥ 35 years), heavier (BMI ≥ 24 kg/m2), or had poorer ovarian reserve AFC<6 or basal FSH>10 IU/L or AMH <1 ng/ml. Conversely, if the woman is lean (BMI < 19 kg/m2) or has a good ovarian reserve (AFC≥ 15 or AMH≥ 4 ng/ml), the dosage will be reduced. Dose adjustments were determined by the physician based on individual clinical experiences. GnRH antagonists (Cetrorelix, BaxterorGanirelix, N.V.Organon) were given daily starting on day 5 or 6 of stimulation. Human chorionic gonadotrophin (Chorionic Gonadotrophin for Injection, Livzon) was injected once there were at least three follicles >17 mm in diameter or at least two follicles >18 mm in diameter. Oocyte retrieval was performed under ultrasound guidance 34-36 hours after triggering.
Full text: Click here
Publication 2023
antagonists Biological Assay cetrorelix Diagnosis Gonadorelin Gonadotropins Gonal F Graafian Follicle Hair Follicle Human Chorionic Gonadotropin Hydrocortisone Immunoassay livzon Menstrual Cycle Oocyte Retrieval Ovarian Reserve Ovarian Stimulation Physicians Progesterone Puregon Serum Treatment Protocols Ultrasonography Woman
Conventional agonist or antagonist stimulation protocols were used for ovarian stimulation as previously described (Cai et al., 2017 (link)). The initial and ongoing dosage was determined according to patients’ age, antral follicle count (AFC), BMI, and ovarian response. An intramuscular injection of human chorionic gonadotropin (4000–6000 IU, hCG; Livzen, China) or a subcutaneous injection of recombinant human chorionic gonadotropin (250 μg, Ovidrel, Merck-Serono, Switzerland) was administrated for final triggering when at least one follicle reached a mean diameter of 18 mm. Ovum puncture under transvaginal ultrasound guidance for oocyte retrieval was performed 34–36 h after hCG injection.
Routine IVF protocol in our center was carried out (Jiang et al., 2022 (link)). Cumulus-oocyte complexes were co-cultured with approximate 1.5–3 X 105 progressively motile spermatozoa in pre-equilibrated fertilization culture medium (K-SIFM, Cook) under mineral oil in traditional incubators (C200, Labotect) at 37°C, 6% CO2 and 5% O2 in a humidified atmosphere. After 4 h co-culture, oocytes were denuded and cultured individually in preequilibrated Cleavage Medium (K-SICM, Cook). The culture system and the procedure of semen preparation were kept unchanged in the period of study. Fertilization was determined according to the presence of two pronuclei (2 PN) about 17 h post insemination. It should be confirmed 2 h later if no obvious pronuclei could be observed.
Full text: Click here
Publication 2023
Atmosphere Coculture Techniques Cytokinesis Fertilization fibroblast chemotactic inhibitor Graafian Follicle Human Chorionic Gonadotropin Insemination Intramuscular Injection Oil, Mineral Oocyte Retrieval Oocytes Ovarian Follicle Ovarian Stimulation Ovary Ovidrel Ovum Patients Plant Embryos Punctures Sperm Subcutaneous Injections Ultrasonography
Paraffin-embedded ovaries were serially sectioned. The first section containing ovarian tissue was collected. Every six sections, another section was collected until 20 sections were collected. HE staining was performed to evaluate the morphology of follicles. The criteria for the classification of follicles are as follows: primordial follicle, the oocyte was enclosed by a layer of squamous granulosa cells; primary follicle, the oocyte was enclosed by cuboidal granulosa cells; secondary follicle, the oocyte was enclosed by 2 or more layers of granulosa cells; and antral follicle, an antrum cavity was present. We avoided recording the same follicle more than once.
Full text: Click here
Publication 2023
Antral Cuboid Bone Dental Caries Graafian Follicle Granulosa Cell Hair Follicle Oocytes Ovarian Follicle Ovary Paraffin Tissues
Serial 8-μm sections were cut from paraffin-embedded adult ovaries. All follicles or oocytes in VASA immunostained ovarian sections were counted. Follicle types were classified according to the following structural characteristics. As described previously [67 (link)], the following follicle types were distinguished: primordial follicles (type 1 and type 2), primary follicles (type 3), secondary follicles (type 4 and type 5), and antral follicles (types 6 − 8).
Serial 5-μm sections were obtained from paraffin-embedded ovaries from 5 dpp and newborn mice. The sections were stained with haematoxylin, and the following categories of oocytes and follicles were counted in every fifth section: primordial follicles (oocytes approximately 20 μm in diameter surrounded by 3 − 5 flat pregranulosa cells each); oocytes in cysts (two or more oocytes with shared cytoplasm); and naked oocytes (oocytes without any granulosa cells). As described previously [68 (link)], the sum of these counts was multiplied by five to estimate the total number of oocytes and follicles in each ovary.
Full text: Click here
Publication 2023
Adult Cells Cyst Cytoplasm Graafian Follicle Granulosa Cell Hair Follicle Infant, Newborn Mus Oocytes Ovarian Follicle Ovary Paraffin Embedding

Top products related to «Graafian Follicle»

Sourced in Switzerland, Germany, Italy, France, United States, Spain, Netherlands, United Kingdom, Australia, Japan, Denmark, Brazil, China
Gonal-F is a recombinant human follicle-stimulating hormone (r-hFSH) produced by recombinant DNA technology. It is used as a fertility medication to stimulate follicular development and maturation in the ovary as part of an assisted reproductive technology (ART) program.
Sourced in United States, China, United Kingdom, Germany, Australia, Japan, Canada, Italy, France, Switzerland, New Zealand, Brazil, Belgium, India, Spain, Israel, Austria, Poland, Ireland, Sweden, Macao, Netherlands, Denmark, Cameroon, Singapore, Portugal, Argentina, Holy See (Vatican City State), Morocco, Uruguay, Mexico, Thailand, Sao Tome and Principe, Hungary, Panama, Hong Kong, Norway, United Arab Emirates, Czechia, Russian Federation, Chile, Moldova, Republic of, Gabon, Palestine, State of, Saudi Arabia, Senegal
Fetal Bovine Serum (FBS) is a cell culture supplement derived from the blood of bovine fetuses. FBS provides a source of proteins, growth factors, and other components that support the growth and maintenance of various cell types in in vitro cell culture applications.
Sourced in United States, Spain, Canada, Denmark, Belgium, Japan
TCM-199 is a cell culture medium developed for the in vitro cultivation of various cell types, including mammalian cells. It provides the necessary nutrients and growth factors to support cell growth and maintenance. The formulation is designed to maintain the physiological pH and osmolality required for optimal cell performance.
Sourced in United States, Switzerland, Germany, China, United Kingdom, Canada, Israel, Macao, Sao Tome and Principe, Japan
The HCG (Human Chorionic Gonadotropin) is a laboratory equipment product by Merck Group. It is a hormone typically used in various diagnostic and research applications. The core function of HCG is to detect and measure the levels of this hormone in biological samples.
Sourced in Germany, Switzerland, United Kingdom, Spain, France, Netherlands, United States, Japan
Cetrotide is a laboratory product manufactured by Merck Group. It is a synthetic peptide that acts as a gonadotropin-releasing hormone (GnRH) antagonist. The core function of Cetrotide is to inhibit the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from the pituitary gland.
Sourced in Germany, Switzerland, France, Italy, United Kingdom, Netherlands
Ovitrelle is a laboratory product manufactured by Merck Group. It is a gonadotropin-releasing hormone agonist used in in-vitro fertilization procedures.
Sourced in United States, Germany, Switzerland, United Kingdom, Japan, China, Italy, France, Macao, Israel, Australia, Sao Tome and Principe, Canada, Spain, Netherlands, Czechia
Hyaluronidase is an enzyme used in laboratory settings. It functions by breaking down hyaluronic acid, a component of the extracellular matrix.
Sourced in United States, Germany, United Kingdom, France, Japan
M2 medium is a cell culture media formulation designed for the maintenance and cultivation of mouse embryos. It provides the necessary nutrients and growth factors to support the development and growth of mouse embryos in an in vitro environment.
Sourced in Switzerland, Germany, Italy, United States, Brazil, Australia
Ovidrel is a laboratory product manufactured by Merck Group. It is a recombinant human chorionic gonadotropin (hCG) medication used for in vitro fertilization (IVF) procedures. Ovidrel is designed to trigger the final stage of egg maturation prior to ovulation.
Sourced in United States, Germany, United Kingdom, China, Canada, France, Japan, Australia, Switzerland, Israel, Italy, Belgium, Austria, Spain, Gabon, Ireland, New Zealand, Sweden, Netherlands, Denmark, Brazil, Macao, India, Singapore, Poland, Argentina, Cameroon, Uruguay, Morocco, Panama, Colombia, Holy See (Vatican City State), Hungary, Norway, Portugal, Mexico, Thailand, Palestine, State of, Finland, Moldova, Republic of, Jamaica, Czechia
Penicillin/streptomycin is a commonly used antibiotic solution for cell culture applications. It contains a combination of penicillin and streptomycin, which are broad-spectrum antibiotics that inhibit the growth of both Gram-positive and Gram-negative bacteria.

More about "Graafian Follicle"

The Graafian follicle is a crucial component of the female reproductive system, also known as the mature ovarian follicle or the Regnier de Graaf follicle.
This structure plays a vital role in the menstrual cycle, containing a secondary oocyte and preparing for ovulation.
Researchers studying the Graafian follicle can utilize advanced tools like PubCompare.ai to optimize their research protocols, explore a vast library of relevant literature, preprints, and patents, and find the best protocols and products using intelligent comparisons.
This can help take the guesswork out of their research.
When studying the Graafian follicle, researchers may also explore related topics and products, such as Gonal-F (a follicle-stimulating hormone), fetal bovine serum (FBS), TCM-199 (a cell culture medium), human chorionic gonadotropin (HCG), Cetrotide (a gonadotropin-releasing hormone antagonist), Ovitrelle (a recombinant HCG), hyaluronidase (an enzyme that aids in follicle rupture), M2 medium (a culture medium for oocytes), Ovidrel (a recombinant HCG), and penicillin/streptomycin (antibiotics used in cell culture).
By leveraging the insights and tools provided by platforms like PubCompare.ai, researchers can streamline their Graafian follicle studies and make more informed decisions throughout the research process.